Navigation Links
Edison Expands its Asia-Pac Pharmaceutical Presence with Launch of Coverage of Mesoblast
Date:11/27/2013

LONDON, November 27, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of coverage of Mesoblast (MSB: ASX), an Australian-headquartered biotechnology company focused on adult stem therapies.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168)

Mesoblast's pipeline is based on its proprietary mesenchymal precursor cell (MPC) and culture-expanded mesenchymal stem cell (MSC) technologies. Edison's report, Precursor to success, discusses Mesoblast's two technology platforms (MPCs and MSCs) that have to date generated nine clinical candidates (four in Phase III, five in Phase II). The report goes on to analyse the three strategic partnerships with Teva, JCR and Lonza, which underpin the key late-stage programmes including Revascor that could provide US$4bn potential peak sales.

Edison's healthcare team value Mesoblast at A$2.6bn (A$8.07/share) based on a risk-adjusted net present value (rNPV) analysis, which could rise to A$3.2bn (A$10.00/share) if upcoming catalysts are positive.

For the full report see: http://www.edisoninvestmentresearch.com/research/company/mesoblast

About Edison Investment Research

The launch of coverage on Mesoblast is part of a programme of research initiations on biotechnology companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services
'/>"/>

SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Edison expands international bio-pharmaceutical presence with launch of coverage of Onconova Therapeutics
2. Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients
3. Edison initiates coverage of Derma Sciences
4. Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
5. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
6. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
7. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
8. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
9. Edison Pharmaceuticals Closes $20M Series F Financing
10. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
11. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Calif. , Aug. 27, 2014 Asterias ... U.S. Food and Drug Administration (FDA) to initiate a ... patients with complete cervical spinal cord injury.  The approved ... clinical study of the product, and is designed to ... in patients with complete cervical spinal cord injuries, the ...
(Date:8/26/2014)... Aug. 26, 2014  Kewaunee Scientific Corporation (Nasdaq: ... quarter ended July 31, 2014. Sales for ... $32,003,000 in the first quarter last year. Net earnings ... share, as compared to net earnings of $1,587,000, or ... the prior year. However, both sales and earnings in ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) ... two fidaxomicin Phase 3 trials in patients with ... Meeting of the Infectious Disease Society of America (IDSA) ... investigator Derrick Crook, M.D., of the University of Oxford, ...
... leading home health care and hospice company (Nasdaq: AMED ... home care in this week,s issue of the New England Journal ... Advisory Board. Titled, "Why Health Care is Going ... home care as an increasingly crucial component of America,s health care ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Media Statement From Amedisys on Dr. Steven H. Landers' NEJM Commentary on the Future of Home Care 2
(Date:8/27/2014)... to market research report, “Variable Frequency Drives Market by ... High), Voltage (Low & Medium), Application (Pump, Fan, Compressor, ... & Forecast to 2019” defines and segments the global ... of the market size. The variable frequency drives market ... to $22.73 billion by 2019, with a CAGR of ...
(Date:8/27/2014)... 27, 2014 Specialty Technical Publishers (STP) ... International Audit Protocol Consortium (IAPC) EHS audit protocol for ... around the world use IAPC EHS audit protocols to ... rapidly collect, share, archive, and export audit findings in ... are prepared by AECOM in partnership with STP and ...
(Date:8/27/2014)... Main Street Dental Team ( MainStreetDentalTeam.com ), ... how long a toothbrush can be used before it has ... teeth and gums. , “Replacing a toothbrush is something that ... Dr. Harvey Schwartz, owner of Main Street Dental Team. “Using ... months." , Dr. Schwartz explains that what’s important to keep ...
(Date:8/27/2014)... Top10inaction, a professional website reveals the best ... by name brands such as Apple, Samsung, Sony, Blackberry ... means a lot more than just a device of ... surf the internet with their little toys. And just ... to choose a right smartphone has become a dilemma. ...
(Date:8/27/2014)... DC (PRWEB) August 27, 2014 ... Diplomat University were announced as the winners of ... August issue of Atlantic Information Services, Inc.’s ... penned by the company’s founder and Principal Consultant ... were commended for meeting the true definition of ...
Breaking Medicine News(10 mins):Health News:Variable Frequency Drives Market Worth $22.73 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Specialty Technical Publishers and AECOM Publish Environmental, Health & Safety (EHS) Audit Protocol for Brazil (and the State of São Paulo) 2Health News:Specialty Technical Publishers and AECOM Publish Environmental, Health & Safety (EHS) Audit Protocol for Brazil (and the State of São Paulo) 3Health News:Specialty Technical Publishers and AECOM Publish Environmental, Health & Safety (EHS) Audit Protocol for Brazil (and the State of São Paulo) 4Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Advises on the Best Time to Replace a Toothbrush 2Health News:Best Smartphones 2014 Revealed by Top10InAction.com 2Health News:Specialty Pharmacy Solutions Founder Reveals Winners of Innovation Competition in August Issue of AIS Newsletter 2Health News:Specialty Pharmacy Solutions Founder Reveals Winners of Innovation Competition in August Issue of AIS Newsletter 3
... Will Highlight Hurdles To Government Oversight & Gaining ... ... Without an improved,governance structure, the benefits of nanotechnology may be difficult ... David Rejeski, director of the Project on Emerging,Nanotechnologies (PEN). Rejeski testifies ...
... 10,000 University of California RNs to ... Bargain Over Improved Patient Safety, OAKLAND, ... the California Nurses Association/National Nurses Organizing,Committee today won a major ... nurses it represents to strike, and to,bargain over improved staffing ...
... Fla., April 22 PainCare Holdings,Inc. (Amex: PRZ ... services, today announced that it received a letter from ... notifying the Company that,its delay in filing its Form ... a failure to comply with the continued listing standards,set ...
... 22 Cardica, Inc.,(Nasdaq: CRDC ) today announced ... quarter ended March 31, 2008, on Tuesday, April 29, ... host a,conference call at 4:30 p.m. Eastern Time to ... company,s business., Conference Call Details, To access ...
... (Nasdaq: UAHC ) today announced that the ... Tennessee, Bureau of TennCare,(,TennCare,), today publicly disclosed its ... organizations, not including the company,s,subsidiary, UAHC Health Plan ... of TennCare,s selection process pursuant to its Request ...
... use of cisplatin no better than standard treatment, researchers ... Compared to the standard treatment regimen for anal canal ... other treatments didn,t improve disease-free survival and resulted in ... study. , Currently, the preferred primary therapy for patients ...
Cached Medicine News:Health News:Improved Governance Needed To Realize Nanotech's Benefits 2Health News:CNA/NNOC Wins Key Legal Decision Protecting Right of Public Employees to Strike 2Health News:PainCare Receives Notices From American Stock Exchange 2Health News:PainCare Receives Notices From American Stock Exchange 3Health News:PainCare Receives Notices From American Stock Exchange 4Health News:Cardica to Announce Fiscal 2008 Third Quarter Financial Results on Tuesday, April 29, 2008 2Health News:United American Healthcare Corporation Provides Update on TennCare RFP Awards 2Health News:New Anal Cancer Therapy Fails to Improve Outcomes 2
Inquire...
... damaged fiber optics reduce the light output to ... in the optical clarity that is so vital. ... essential to prevent further damage and more extensive ... can inspect your cables for you at no ...
Inquire...
... inspects your equipment upon arrival. Our technician then ... provides you with a thorough customer quote. We ... tight budget so well help you prioritize repairs. ... begins., , ISI uses only OEM or widely ...
Medicine Products: